Dynex Capital Declares $0.17 Cash Dividend for January 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Newsfilter
- Dividend Announcement: Dynex Capital's Board of Directors has declared a cash dividend of $0.17 per common share for January 2026, reflecting the company's commitment to ongoing shareholder returns, which is expected to bolster investor confidence.
- Dividend Payment Date: The dividend will be payable on February 2, 2026, to shareholders of record on January 21, 2026, ensuring timely returns for investors and further solidifying the relationship between the company and its shareholders.
- Operational Model: As a real estate investment trust (REIT), Dynex Capital focuses on transforming residential real estate into long-term yields, highlighting its significant role in the U.S. housing finance system and aiming to provide stable returns for shareholders.
- Risk Management Commitment: The company emphasizes its expertise in capital allocation and risk management, dedicated to supporting the growth and vitality of housing communities in the U.S. through ethical stewardship and social responsibility, showcasing its commitment to sustainable development.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like DX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on DX
Wall Street analysts forecast DX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DX is 15.25 USD with a low forecast of 14.50 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.640
Low
14.50
Averages
15.25
High
16.00
Current: 14.640
Low
14.50
Averages
15.25
High
16.00
About DX
Dynex Capital, Inc. is a financial services company. The Company is an internally managed mortgage real estate investment trust (REIT), which invests in mortgage-backed securities (MBS). It finances its investments principally with repurchase agreements. Its objective is to provide attractive risk-adjusted returns to its shareholders over the long term that are reflective of a leveraged, high-quality fixed income portfolio with a focus on capital preservation. It seeks to provide returns to its shareholders primarily through the payment of regular dividends and through capital appreciation of its investments. It primarily invests in Agency MBS, of which over 97% are residential MBS (Agency RMBS), including to-be-announced (TBA) securities. The remainder of its investment portfolio consists of Agency commercial MBS (Agency CMBS) and Agency and non-Agency CMBS interest-only (CMBS IO) securities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dynex Capital Increases Share Availability by 60M
- Increased Share Availability: Dynex Capital announced an amendment to its distribution agreement, increasing the number of shares available for sale by 60 million to a total of 221.29 million shares, enhancing market liquidity and providing more options for future financing.
- Remaining Issuable Shares: The company has 67.35 million shares still available for issuance, which supports its flexible operations in the capital markets and helps address future funding needs.
- Enhanced Shareholder Returns: While raising $1.5 billion in capital, Dynex signals a shift to a tighter spread regime, expected to yield a 29.4% return for shareholders, thereby boosting investor confidence.
- Financial Performance Fluctuations: Despite a decline in Q4 earnings due to rising expenses, the company reported increases in book value and net interest income, indicating a degree of financial health amidst challenges.
Continue Reading
Wall Street Analysts Adjust Ratings
- Acumen Price Target Raised: BTIG raised Acumen Pharmaceuticals' price target from $4 to $7, with analyst Thomas Shrader maintaining a Buy rating, indicating confidence in the company's growth potential despite a closing price of $2.08 on Monday.
- Exelixis Target Price Increase: HC Wainwright & Co. raised the price target for Exelixis from $49 to $52, with analyst Robert Burns maintaining a Buy rating, reflecting optimism about its market performance, closing at $43.61 on Monday.
- Baker Hughes Price Target Upgraded: BMO Capital increased Baker Hughes' price target from $55 to $65, with analyst Phillip Jungwirth maintaining an Outperform rating, suggesting a positive outlook on its future performance, closing at $56.29 on Monday.
- Brown & Brown Price Target Cut: B of A Securities lowered the price target for Brown & Brown from $94 to $90, with analyst Joshua Shanker maintaining a Neutral rating, indicating a cautious stance on the company's short-term performance, closing at $79.62 on Monday.
Continue Reading